Drawing for CHIMERA

USPTO serial 98963710

CHIMERA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
KRUSSMAN, IAN GEORGE
Law office
TMO LAW OFFICE 126

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with CHIMERA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Robert S. Broder

Robert S. Broder Collard & Roe, P.C.1077 Northern Blvd.Roslyn, NY 11576United States

Goods and services

ClassDescriptionStatusFirst use
001Chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with amplification, analysis or labelling of nucleic acid; Nucleic acid sequences and chemical reagents for other than medical and veterinary purposes; Nucleic acid for laboratory use; Nucleic acids, other than for medical or veterinary purposes; Nucleic acid sequences, other than for medical or veterinary purposes; Reagents for scientific purposes for use in nucleic acid isolation and purification; Reagents for scientific purposes; Nucleic acids for scientific purposes; Nucleic acid sequences and chemical reagents for medical and veterinary purposes; Nucleic acids for medical or veterinary purposes; Genetic identity tests comprised of reagents for non-medical purposes; Assays and reagents for use in genetic research; Biochemicals, namely, precursors for in vitro genetic engineering use; Chemical reagents for use in genetic researchACTIVE—
005Reagents for use in medical genetic testing; Genetic identity tests comprised of reagents for medical purposes; Preparations for detecting genetic predispositions for medical purposes; Diagnostic preparations for medical purposes for detecting genetic predispositions; Preparations for detecting mutation in prion genes for medical purposes; Diagnostic preparations for medical purposes for detecting mutation in prion genesACTIVE—
042Scientific research in the field of genetics; Consulting services in the field of genetic science; Research in the field of DNA mutation; Research in the field of DNA mutation, namely, chimerism; DNA screening for scientific research purposes; DNA screening for scientific research purposes, namely, chimerism; DNA analysis services to determine paternity; DNA sequencing technology research; Providing scientific research information in the field of genotyping; Providing scientific research information in the field of identification of chimerisms; Providing genetic science information; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Genetic testing for scientific research purposes; Genetic fingerprinting services; Genetic fingerprinting services for forensic purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Oct 8, 2025MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 8, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 24, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2025DOCKASSIGNED TO EXAMINER—
Jan 15, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 15, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance